Individualisation of drug treatments for patients with long-term conditions: A review of concepts

BMJ Open

Volumn 4, Issue 3, 2014, Pages

  Denford, Sara ^a   Frost, J ^a   Dieppe, P ^a   Cooper, Chris ^a   Britten, N ^a  

^a UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG MONITORING; HEALTH CARE PERSONNEL; HUMAN; PATIENT PARTICIPATION; PERSONALIZED MEDICINE; PHARMACOGENETICS; REVIEW; CHRONIC DISEASE; DISEASE MANAGEMENT; DOCTOR PATIENT RELATION; SELF CARE;

CHRONIC DISEASE; DISEASE MANAGEMENT; HUMANS; PATIENT PARTICIPATION; PHARMACOGENETICS; PHYSICIAN-PATIENT RELATIONS; SELF CARE;

EID: 84897473870     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-004172     Document Type: Review

References (44)

1. Department of Health. Equity and excellence. Norwich: Liberating the NHS, 2010.
2. Politi C, Dizon D, Frosch DL, et al. Importance of clarifying patients' desired role in shared decision making to match their level of engagement with their preferences. BMJ 2013;347:f7066.
3. Denford S, Frost J, Dieppe P, et al. Doctors' understanding of individualisation of drug treatments: a qualitative interview study. BMJ Open 2013;3:e002706.
4. Chalmers I, Glasziou P. Avoidable waste in the production and reporting of research evidence. Lancet 2009;374:86-9.
5. Whear R, Thompson-Coon J, Boddy K, et al. Establishing local priorities for a health research agenda. Health Expect 2012. doi:10.1111/hex.12029
6. May C, Montori V, Mair F. We need minimally disruptive medicine. BMJ 2009;12:339.
7. Pound P, Britten N, Morgan M, et al. Resisting medicines: a synthesis of qualitative studies of medicine taking. Soc Sci Med 2005;61:133-55. (Pubitemid 40545066)
8. Armstrong R, Hall BJ, Doyle J, et al. Cochrane update. 'Scoping the scope' of a Cochrane review. J Public Health (Oxf) 2011;33:147-50.
9. Booth A. Unpacking your literature search toolbox: on search styles and tactics. Health Info Libr J 2008;25:313-17.
10. Uddin S, Hossain L, Rasmussen K. Network effects on scientific collaborations. PLoS ONE 2013;8:e57546.
11. Ritchie J, Spencer L. Qualitative data analysis for applied policy research. In: Bryman A, Burgess RG. eds. Analysing qualitative data. New York: Routledge, 2000:173.
12. Miles MB, Huberman AM. Qualitative data analysis: an expanded sourcebook. 2nd edn. Thousand Oaks: Sage Publications, 1994.
13. Szefler SJ. Personalised medicine for asthma management in pregnancy. Lancet 2011;378:963-4.
14. The Academy of Medical Sciences. Realising the potential of stratified medicine. London: AMS, 2013.
15. Personalized Medicine Coalition. 2013. http://www. personalizedmedicinecoalition.org/ (accessed Jul 2013).
16. Kumar D. The personalised medicine. A paradigm of evidence-based medicine. Ann Ist Super Sanita 2011;47:31-40.
17. Blum HE. Individualized medicine 2010. J Cell Mol Med 2010;14:2257-63.
18. Fierz W. Challenge of personalized health care: to what extent is medicine already individualised and what are the future trends. Med Sci Monit 2004;10:111-23.
19. Pfaff H, Driller E, Ernsmann N, et al. Standardization through individualization in care for the elderly: proactive behaviour through individualized standardization. Open Longev Sci 2010;4:51-7.
20. European Science Foundation. Personalised medicine for the European citizen: towards more precise medicine for the diagnosis, treatment and prevention of disease. Strasbourg, France: ESF, 2012.
21. Nuffield Council on Bioethics. Medical profiling and online medicine: the ethics of personalized healthcare in a consumer age. Oxford: Nuffield Council on Bioethics, 2010.
22. Kitsios GD, Kent DM. Personalised medicine: not just in our genes. BMJ 2012;344:e2161.
23. Burgener SC, Shimer R, Murrell L. Expressions of individuality in cognitively impaired elders: need for individual assessment and care. J Gerontol Nurs 1993;19:13-22.
24. Corrigan O. Personalized medicine in a consumer age. Curr Pharmacogenomics Person Med 2011;9:168-76.
25. Luijks HD, Loeffen MJ, Lagro-Janssen AL, et al. GPs' considerations in multimorbidity management: a qualitative study. Br J Gen Pract 2012;62:e503-10.
26. Kassirer JP. Incorporating patients' preferences into medical decisions. N Engl J Med 1994;330:1895-6. (Pubitemid 24188144)
27. Bassler D, Busse JW, Karanicolas PJ, et al. Evidence-based medicine targets the individual patient, part 2: guides and tools for individual decision-making. Evid Based Med 2008;13:130-1.
28. Tutton R. Personalizing medicine: futures present and past. Soc Sci Med 2012;75:1721-8.
29. Picton C. Moving towards personalizing medicines management. Liverpool: National Prescribing Centre, 2008. http://www.npc.nhs.uk/resources/ personalising-medicines-management-web.pdf (accessed Dec 2013).
30. Radwin LE, Alster K. Individualized nursing care: an empirically generated definition. Int Nurs Rev 2002;49:54-63.
31. Cribb A, Owens J. Whatever suits you: unpicking personalization for the NHS. J Eval Clin Pract 2010;16:310-14.
32. Moldrup C. Beyond personalized medicine. Per Med 2009;6:231-3.
33. Hoffmann W, Krafczyk-Korth J, Valzke H, et al. Towards a unified concept of individualized medicine. Per Med 2011;8:111-13.
34. Lavori PW, Dawson R, Rush AJ. Flexible treatment strategies in chronic disease: clinical and research implications. Biol Psychiatry 2000;48:605-14.
35. Glasziou P, Irwig L, Mant D. Monitoring in chronic disease: a rational approach. BMJ 2005;330:644-8. (Pubitemid 40444763)
36. Vardos P. Personalised health care: an emerging aim. Hellenic J Cardiol 2008;49:453.
37. Mangia A, Minerva N, Bacca D, et al. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology 2008;47:43-50. (Pubitemid 351171040)
38. Strain WD, Lukashevich V, Kothny W, et al. Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study. Lancet 2013;382:409-16.
39. Heisler M. Actively engaging patients in treatment decision making and monitoring as a strategy to improve hypertension outcomes in diabetes mellitus. Circulation 2008;117:1355-7. (Pubitemid 351501487)
40. Naik AD, Kallen MA, Walder A, et al. Improving hypertension control in diabetes mellitus: the effects of collaborative and proactive health communication. Circulation 2008;117:1361-8. (Pubitemid 351501489)
41. McManus RJ, Mant J, Bray EP, et al. Telemonitoring and self-management in the control of hypertension (TASMINH2): a randomised controlled trial. Lancet 2010;376:163-72.
42. Gabler NB, Duan N, Vohra S, et al. N-of-1 trials in the medical literature: a systematic review. Med Care 2011;49:761-8.
43. Nikles CJ, Yelland M, Glasziou PP, et al. Do individualized medication effectiveness tests (N-of-1 trials) change clinical decisions about which drugs to use for osteoarthritis and chronic pain? Am J Ther 2005;12:92-7. (Pubitemid 40516050)
44. The King's Fund. Polypharmacy and medicines optimisation. Making it safe and sound. London: The King's Fund, 2013. http://www.kingsfund.org.uk/sites/ files/kf/field/field-publication-file/polypharmacy-and-medicines-optimisation- kingsfund-nov13.pdf (accessed Dec 2013).